1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

 
• By Joseph Haas

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments

Amicus Therapeutics Inc. Chairman and CEO John Crowley was apologetic – and also adamant about trial quality – upon announcing Sept. 13 that the biotech will drop further development of SD101 for epidermolysis bullosa (EB) after a Phase III trial failed to meet its two co-primary endpoints and all of its secondary endpoints.

Crowley offered hope to EB patients, their clinicians and caregivers during a same-day investor call by noting that several other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Dynavax Aims To Disrupt GSK’s Shingrix Market With More Tolerable Shingles Vaccine

 
• By Mandy Jackson

Phase I/II head-to-head data show Dynavax’s Z-1018 had similar immunogenicity and much improved tolerability versus Shingrix, prompting a move into Part 2 of the study.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

More from R&D

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger